From what I have read there were 2 trials, the AFFIRM and the SENTINEL.
One with the medication alone and the other was the medication with Avonex. Which of these trials showed the 66% reduction? My daughter's neuro wants her to stay on the Betaseron and start on the infusions. He thinks I might have problems with my insurance covering both medications. With the price of those meds there is no way that I could ...

Woohoo!!!


FDA Grants Accelerated Approval of TYSABRI, Formerly ANTEGREN, For the Treatment of Multiple Sclerosis

Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) announced today that the U.S. Food and Drug Administration (FDA) has approved TYSABRI(R) (natalizumab), formerly referred to as ANTEGREN(R), as treatment for relapsing forms of multiple sclerosis (MS) to reduce the frequency of clinical relapses. FDA granted Accelerated Approval for TYSABRI following Priority Review based on one-year data from two ...

The exchange of views that we had in the thread “Antegren - Debunking Urban Myths” was useful to the degree that differing viewpoints were exchanged. It was counterproductive, however, in that the language that I used led to both of you being insulted and offended. I apologize that my words have caused you distress. Whatever my enthusiasm for my position, the exchange of views ended badly, and I take the blame for the result.

I ...

This topic has been removed...

bNot sure if this was posted here, but thought it should be.

http://www.abstracts2view.com/aan/sessionindex.php

(you have to register to search abstracts - its free to register, then search on natalizumab.)

Presented at the 56th AAN Annual Meeting in San Francisco:

1. Single-Patient Study for the Emergency Use of Natalizumab (Antegran) in the Treatment of Pediatric Multiple Sclerosis
Authors: Shehzad Choudry, Shane Maxwell, Douglas R. Jeffery, Wisnton-Salem, NC, Michael Panzara, ...

Don't know if you've all seen this before, it came out a little while ago, but I thought it might be of interest here.


Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects.

O'Connor PW, Goodman A, Willmer-Hulme AJ, Libonati MA, Metz L, Murray RS, Sheremata WA, Vollmer TL, Stone LA; Natalizumab Multiple Sclerosis Trial Group.

St. Michael's Hospital, Toronto, Ontario, Canada. oconnorp@smh.toronto.on.ca

BACKGROUND: Relapses in ...

I just now saw the NMSS's bulletin regarding Antegren that was just posted on their website (dated 11-8-04).

Well, I have to say (for what it's worth), that I approve. I couldn't have worded it better myself for them (given their "leadership" role in MS). :wink:

They basically are doing what I said I was doing just a minute ago. Letting the FDA deal with it. HAH! ...

From: http://www.wddty.co.uk/archive/e-news%2 ... 02003.html

Medicine in general—and the pharmaceutical industry in particular—live for the ‘next best thing’, the breakthrough discovery that will change the course of a disease.

Take, for instance, a monoclonal antibody drug called Antegren (natalizumab). Two studies that appear in the same issue of the prestigious New England Journal of Medicine show that Antegren can improve the quality of life for sufferers of acute Crohn’s disease, ...

Some of you may find this interesting.

In talking about Antegren, and pharmas, etc., I mentioned SEC filings. So........I took a quick look at SEC filings for Biogen Idec. This is ALL public record and can be found on their website, not to mention on the Securities and Exchange Commission website.

I'm going to highlight what I found a little "surprising" in a way. Not very "diversified" are they? That's a little risky in my ...